Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated a new insulin delivery system designed to reduce insulin delivery when trends in continuous glucose monitoring (CGM) glucose concentrations predict future hypoglycemia. RESEARCH DESIGN AND METHODS: Individuals with type 1 diabetes (n = 103, age 6–72 years, mean HbA1c 7.3% [56 mmol/mol]) participated in a 6-week randomized crossover trial to evaluate the efficacy and safety of a Tandem Diabetes Care t:slim X2 pump with Basal-IQ integrated with a Dexcom G5 sensor and a predictive low-glucose suspend algorithm (PLGS) compared with sensor-augmented pump (SAP) therapy. The primary outcome was CGM-measured time <70 mg/dL. RESULTS: Both study periods were completed by 99% of participants; median CGM usage exceeded 90% in both arms. Median time <70 mg/dL was reduced from 3.6% at baseline to 2.6% during the 3-week period in the PLGS arm compared with 3.2% in the SAP arm (difference [PLGS − SAP] = −0.8%, 95% CI −1.1 to −0.5, P < 0.001). The corresponding mean values were 4.4%, 3.1%, and 4.5%, respectively, represent-ing a 31% reduction in the time <70 mg/dL with PLGS. There was no increase in mean glucose concentration (159 vs. 159 mg/dL, P = 0.40) or percentage of time spent >180 mg/dL (32% vs. 33%, P = 0.12). One severe hypoglycemic event occurred in the SAP arm and none in the PLGS arm. Mean pump suspension time was 104 min/day. CONCLUSIONS: The Tandem Diabetes Care Basal-IQ PLGS system significantly reduced hypoglycemia without rebound hyperglycemia, indicating that the system can benefit adults and youth with type 1 diabetes in improving glycemic control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Partial closed-loop therapy, such as predictive low-glucose suspend (PLGS) technology, has been shown in nonpregnant people to be better than sensoraugmented insulin pumps (SAP) for reducing low glucose values (108).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [108]
In the citing paper
“Both generation 1 low-glucose-suspend33 and generation 2 hybrid closed-loop systems improve glycated haemoglobin concentrations, the time in target range and the time below target range in children, adolescents34 and adults.35-37”
From Blood glucose monitoring devices: current considerations (2023) · cites this paper as [33]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [25]
In the citing paper
“Predictive lowglucose suspend systems have been shown to reduce time spent with glucose <70 mg/dL without rebound hyperglycemia during a 6-week randomized crossover trial (190).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [190]
Citations
Cites
Adaptive linear step-up procedures that control the false discovery rate
Benjamini, Y., Krieger, A. M., & Yekutieli, D. (2006) · Biometrika · doi:10.1093/biomet/93.3.491 · Cited by 3,228 · cited 1×
“All nominal (uncorrected) P values except those from the primary and safety analyses were adjusted for multiple comparisons using the Benjamini-Hochberg adaptive false discovery procedure (24).”
MethodInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“Percentage of time,54 mg/dL was added as a post hoc outcome to conform with a recent consensus classification of hypoglycemia (21).”
MethodSelf-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Estimates of Location Based on Rank Tests
Hodges, J. L., & Lehmann, E. L. (1963) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177704172 · Cited by 1,260 · cited 1×
“parametric analysis based on ranks was performed (23).”
MethodMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 5×
“ticipants using an insulin pump and CGM before the study were higher and baseline HbA1c levels were lower than the national averages for adults and children with type 1 diabetes (9).”
BackgroundInfluentialSelf-citationThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“8% fewer nocturnal hypoglycemia events using a threshold suspend system compared with sensor-augmented pump (SAP) therapy (10).”
MethodSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Determining what individual SUS scores mean
(2009) · Journal of Usability Studies archive · doi:10.5555/2835587.2835589 · Cited by 412
Cited by
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Self-citation15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Self-citationPratley, R. E., Kanapka, L. G., Rickels, M. R., Ahmann, A., Aleppo, G., Beck, R., Bhargava, A., Bode, B. W., Carlson, A., Chaytor, N. S., et al. (2020) · JAMA · doi:10.1001/jama.2020.6928 · Cited by 375
“Diabetes duration, median (IQR) [range], y 39 (24-49) [0.”
Self-citationMaiorino, M. I., Signoriello, S., Maio, A., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2020) · Diabetes Care · doi:10.2337/dc19-1459 · Cited by 364
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
“cemia during a 6-week randomized crossover trial (185).”
Background7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Self-citation7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Self-citationNew closed-loop insulin systems
Boughton, C. K., & Hovorka, R. (2021) · Diabetologia · doi:10.1007/s00125-021-05391-w · Cited by 270
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
Self-citation7. Diabetes Technology: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s007 · Cited by 250
“2% with sensor-augmented pump therapy without predictive low glucose suspend) without rebound hyperglycemia during a 6-week randomized crossover trial (120).”
MethodAdvances in technology for management of type 1 diabetes
Beck, R. W., Bergenstal, R. M., Laffel, L. M., & Pickup, J. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31142-0 · Cited by 242
Self-citation15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s015 · Cited by 232
Self-citation9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
“cemia despite the everyday use of CGM devices (RCT, Limited) [142].”
BackgroundRandomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes
Ware, J., Allen, J. M., Boughton, C. K., Wilinska, M. E., Hartnell, S., Thankamony, A., de Beaufort, C., Schierloh, U., Fröhlich-Reiterer, E., Mader, J. K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111673 · Cited by 222
Self-citation7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Management of Preexisting Diabetes in Pregnancy: A Review
Alexopoulos, A.-S., Blair, R., & Peters, A. L. (2019) · JAMA · doi:10.1001/jama.2019.4981 · Cited by 174
7. Diabetes Technology: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s007 · Cited by 279
Messer, L. H., Berget, C., Vigers, T., Pyle, L., Geno, C., Wadwa, R. P., Driscoll, K. A., & Forlenza, G. P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12971 · Cited by 161
“5 (6-68) for youth, and 30 (3-125) for parents.”
Self-citationISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
“9 mmol/L (<70 mg/dl).(161) Real world registry data from adults using the Tandem systems show a significant reduction in time below range after PLGS start(162) and a 45% risk reduction for sensor time <3.”
MethodReal-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
Pinsker, J. E., Müller, L., Constantin, A., Leas, S., Manning, M., McElwee Malloy, M., Singh, H., & Habif, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0388 · Cited by 147
“19 However, for nonglycemic results, until now, we have only been able to offer limited reports on the software update experience, as PROs were not the focus of prior studies.”
Self-citationBerget, C., Messer, L. H., & Forlenza, G. P. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0091 · Cited by 135
Self-citationContinuous glucose monitoring: The achievement of 100 years of innovation in diabetes technology
Galindo, R. J., & Aleppo, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108502 · Cited by 133
Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions
Templer, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.919942 · Cited by 182
McCall, A. L., Lieb, D. C., Gianchandani, R., MacMaster, H., Maynard, G. A., Murad, M. H., Seaquist, E., Wolfsdorf, J. I., Wright, R. F., & Wiercioch, W. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac596 · Cited by 123
Bosi, E., Choudhary, P., de Valk, H. W., Lablanche, S., Castañeda, J., de Portu, S., Da Silva, J., Ré, R., Vorrink-de Groot, L., Shin, J., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30150-0 · Cited by 125
McAuley, S. A., Trawley, S., Vogrin, S., Ward, G. M., Fourlanos, S., Grills, C. A., Lee, M. H., Alipoor, A. M., O’Neal, D. N., O’Regan, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1667 · Cited by 117
Basal Glucose Control in Type 1 Diabetes Using Deep Reinforcement Learning: An In Silico Validation
Zhu, T., Li, K., Herrero, P., & Georgiou, P. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.3014556 · Cited by 140
Feature-Based Machine Learning Model for Real-Time Hypoglycemia Prediction
Dave, D., DeSalvo, D. J., Haridas, B., McKay, S., Shenoy, A., Koh, C. J., Lawley, M., & Erraguntla, M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820922622 · Cited by 112
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Perkins, B. A., Sherr, J. L., & Mathieu, C. (2021) · Science · doi:10.1126/science.abg4502 · Cited by 122
Biester, T., Berget, C., Boughton, C. K., Cudizio, L., Ekhlaspour, L., Hilliard, M. E., Reddy, L., Sap, S. N. U., Schoelwer, M. J., Sherr, J. L., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543034 · Cited by 124
“A RCT of the Tandem system (Basal-IQ ® ) found that PLGS use led to a 31% reduction in sensor time 3.9 mmol/L ( 70 mg/dL) [164].”
InfluentialSelf-citationAbraham, M. B., Karges, B., Dovč, K., Naranjo, D. M., Arbeláez, A. M., Mbogo, J., Javelikar, G., Jones, T. W., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13443 · Cited by 135
“of basal insulin delivery with hypoglycemia (Low Glucose Suspension)(117,190) and with prediction of hypoglycemia.(4,191) Predictive Low Glucose Management (PLGM) systems include the Medtronic PLGM system and Tandem Basal IQ.”
BackgroundMethodInfluentialA clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm
Messer, L. H., Berget, C., & Forlenza, G. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0105 · Cited by 100
Self-citationCurrent Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Moon, S. J., Jung, I., & Park, C.-Y. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0177 · Cited by 98
“2018 [63] Tandem Dexcom G5 t:slim X2 Basal IQ RCT, crossover 103 6–72 Home 6 weeks PLGS SAP SAP TIR 70–180: 65% vs.”
BackgroundMethodRealizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes
Lal, R. A., Ekhlaspour, L., Hood, K., & Buckingham, B. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00174 · Cited by 95
Self-citationArtificial Intelligence and Machine Learning Applied at the Point of Care
Angehrn, Z., Haldna, L., Zandvliet, A. S., Gil Berglund, E., Zeeuw, J., Amzal, B., Cheung, S. Y. A., Polasek, T. M., Pfister, M., Kerbusch, T., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00759 · Cited by 93
“Marked reduction of sensor time below 3.9 mmol/L (70 mg/dl) was accomplished without any increase in the frequency of hyperglycemia, and patients described the system as simple to learn and use (Forlenza et al., 2018).”
InfluentialBenefits and Challenges of Diabetes Technology Use in Older Adults
Toschi, E., & Munshi, M. N. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.001 · Cited by 91
Tarumi, S., Takeuchi, W., Chalkidis, G., Rodriguez-Loya, S., Kuwata, J., Flynn, M., Turner, K. M., Sakaguchi, F. H., Weir, C., Kramer, H., et al. (2021) · Methods of Information in Medicine · doi:10.1055/s-0041-1728757 · Cited by 84
Evolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132
Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy
Fuchs, J., & Hovorka, R. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1784724 · Cited by 82
The Artificial Pancreas and Type 1 Diabetes
Nwokolo, M., & Hovorka, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad068 · Cited by 119
“…monitoring enabled the development of low-glucose suspend (automated insulin infusion suspension at a set low glucose threshold) and predictive low-glucose suspend pump therapy (insulin infusion suspension in anticipation of an algorithm-predicted low and restart once glucose in target) (5, 6).”
BackgroundAkturk, H. K., Agarwal, S., Hoffecker, L., & Shah, V. N. (2021) · Diabetes Care · doi:10.2337/dc20-3063 · Cited by 81
Basal Glucose Control in Type 1 Diabetes Using Deep Reinforcement Learning: An >In Silico Validation
Zhu, T., Li, K., Herrero, P., & Georgiou, P. (2021) · UCL Discovery (University College London) · Cited by 79
Puhr, S., Derdzinski, M., Welsh, J. B., Parker, A. S., Walker, T., & Price, D. A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0359 · Cited by 78
Zaharieva, D. P., Messer, L. H., Paldus, B., O'Neal, D. N., Maahs, D. M., & Riddell, M. C. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.06.003 · Cited by 84
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
A Multitask Learning Approach to Personalized Blood Glucose Prediction
Daniels, J., Herrero, P., & Georgiou, P. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3100558 · Cited by 97
Reddy, N., Verma, N., & Dungan, K. M. (2020) · MDText.com, Inc. eBooks · Cited by 108
Current Diabetes Technology: Striving for the Artificial Pancreas
Allen, N., & Gupta, A. (2019) · Diagnostics · doi:10.3390/diagnostics9010031 · Cited by 65
“The algorithm works by predicting glucose levels 30 min into the future and suspends insulin delivery if the predicted glucose value is <80 mg/dL or the actual glucose value is <70 mg/dL [45].”
BackgroundTime in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
“Consequently, a broad spectrum of treatment modalities for closing the loop is currently available on the market (in details discussed elsewhere (70)), including low-glucose suspend (71, 72), predictive low-glucose suspend systems MiniMed 640G (Medtronic Diabetes, USA) and Tandem t:slim X2 Insulin Pump with Basal IQ ®…”
Garg, S. K., Grunberger, G., Weinstock, R., Lawson, M. L., Hirsch, I. B., DiMeglio, L. A., Pop-Busui, R., Philis-Tsimikas, A., Kipnes, M., Liljenquist, D. R., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0421 · Cited by 63
“12 The randomized controlled trials of these predictive systems in children, adolescents, or adults demonstrated significantly reduced percentages of time spent below 70 mg/dL (%TBR 70 mg/dL) and below 54 mg/dL (%TBR 54 mg/dL), compared with sensor-augmented pump (SAP) therapy and without…”
Self-citationImproved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts
Abraham, S. B., Arunachalam, S., Zhong, A., Agrawal, P., Cohen, O., & McMahon, C. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819859334 · Cited by 63
Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, E. G., Choudhary, P., Leelarathna, L., & Baxter, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13842 · Cited by 72
“In one study, no difference in GV was found with PLGS technology,(77) while in the other a small improvement in GV was found.(78) Closed-loop systems, also called artificial pancreas or automated”
BackgroundNevo-Shenker, M., & Shalitin, S. (2021) · Hormone Research in Paediatrics · doi:10.1159/000517352 · Cited by 93
Benhalima, K., Beunen, K., Siegelaar, S. E., Painter, R., Murphy, H. R., Feig, D. S., Donovan, L. E., Polsky, S., Buschur, E., Levy, C. J., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00116-x · Cited by 61
Saunders, A., Messer, L. H., & Forlenza, G. P. (2019) · Expert Review of Medical Devices · doi:10.1080/17434440.2019.1670639 · Cited by 62
“When integrated with the Dexcom G6, this pump uses Basal-IQTM technology (Tandem Diabetes Care, San Diego, CA) to reduce occurrences of hypoglycemia through predictive low glucose suspend (PLGS), which is the same concept as suspend before low [15].”
MethodSelf-citationPolonsky, W. H., Hood, K. K., Levy, C. J., MacLeish, S. A., Hirsch, I. B., Brown, S. A., Bode, B. W., Carlson, A. L., Shah, V. N., Weinstock, R. S., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109998 · Cited by 65
Self-citationNovel drug delivery systems: Insight into self-powered and nano-enabled drug delivery systems
Ewii, U. E., Onugwu, A. L., Nwokpor, V. C., Akpaso, I.-A., Ogbulie, T. E., Aharanwa, B., Chijioke, C., Verla, N., Iheme, C. I., Ujowundu, C. O., et al. (2024) · Nano TransMed · doi:10.1016/j.ntm.2024.100042 · Cited by 68
Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations
Bailey, T. S., & Alva, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0236 · Cited by 56
Chamberlain, J. J., Doyle-Delgado, K., Peterson, L., & SKOLNIK, N. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1638 · Cited by 60
“2% in the control group) over 6 weeks without leading to rebound hyperglycemia (36).”
BackgroundGlycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial
Brown, S. A., Beck, R. W., Raghinaru, D., Buckingham, B. A., Laffel, L. M., Wadwa, R. P., Kudva, Y. C., Levy, C. J., Pinsker, J. E., Dassau, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0124 · Cited by 55
“Studies using PLGS report similar hypoglycemia reduction, and most (11,12)”
MethodSelf-citationImproving patient self-care using diabetes technologies
Alcántara-Aragón, V. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818824215 · Cited by 63
Renard, E., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., Kovatchev, B. P., & iDCL Trial Research Group (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 51
Predicting Quality of Overnight Glycaemic Control in Type 1 Diabetes Using Binary Classifiers
Güemes, A., Cappon, G., Hernandez, B., Reddy, M., Oliver, N. S., Georgiou, P., & Herrero, P. (2019) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2019.2938305 · Cited by 57
“Continuous glucose monitoring (CGM) technology [2] has enabled more advanced technologies to support self-management such as sensor-augmented insulin pumps with low-glucose insulin suspend [3], the artificial pancreas [4], and decision support systems (DSS) for insulin dosing [5].”
Developing Insulin Delivery Devices with Glucose Responsiveness
Wang, Z., Wang, J., Kahkoska, A. R., Buse, J. B., & Gu, Z. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.002 · Cited by 54
Modern diabetes devices in the school setting: Perspectives from school nurses
March, C. A., Nanni, M., Kazmerski, T. M., Siminerio, L. M., Miller, E. P., & Libman, I. M. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13015 · Cited by 48
Advances in Type 1 Diabetes Technology Over the Last Decade
Zimmerman, C., University of Florida, G., Albanese-O’Neill, A., University of Florida, G., Haller, M. J., & University of Florida, G. (2019) · European Endocrinology · doi:10.17925/ee.2019.15.2.70 · Cited by 47
“Therefore time in range from 70–180 mg/dL increased slightly from 64% to 65%.(41) T:slim X2 users who also wear the Dexcom G6 are not required to perform finger-sticks for calibrations or insulin delivery.”
BackgroundAutomated insulin delivery in older adults with type 1 diabetes
Kudva, Y. C., Henderson, R. J., Kanapka, L. G., Weinstock, R. S., Rickels, M. R., Pratley, R. E., Chaytor, N., Janess, K., Desjardins, D., Pattan, V., et al. (2025) · NEJM Evidence · doi:10.1056/evidoa2400200 · Cited by 45
Self-citationClosed-loop insulin delivery: update on the state of the field and emerging technologies
Ware, J., & Hovorka, R. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2142556 · Cited by 47
Diabetes Technology Use in Adults with Type 1 and Type 2 Diabetes
Kravarusic, J., & Aleppo, G. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.006 · Cited by 42
Cobry, E. C., Berget, C., Messer, L. H., & Forlenza, G. P. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0055 · Cited by 44
Self-citationArtificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes
Ramli, R., Reddy, M., & Oliver, N. S. (2019) · Drugs · doi:10.1007/s40265-019-01149-2 · Cited by 48
Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 66
Jendle, J., Buompensiere, M. I., Holm, A. L., de Portu, S., Malkin, S. J. P., & Cohen, O. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01157-0 · Cited by 40
“Combinations of CGM and CSII in sensor-augmented pumps (SAPs) can also embed predictive lowglucose management (PLGM) functions that, due to the communication between the two devices, allows partially automated insulin delivery based on blood glucose levels, improving glycemic control and reducing the risk of hypoglyce…”
BackgroundBerget, C., Sherr, J. L., DeSalvo, D. J., KINGMAN, R. S., Stone, S. L., Brown, S. A., Nguyen, A., Barrett, L., Ly, T. T., & Forlenza, G. P. (2021) · Clinical Diabetes · doi:10.2337/cd21-0083 · Cited by 42
Self-citationLiu, C., Vehí, J., Avari, P., Reddy, M., Oliver, N. S., Georgiou, P., & Herrero, P. (2019) · Sensors · doi:10.3390/s19194338 · Cited by 45
“, Medtronic MiniMed 640G with Smart Guard; Tandem t:slim X2TM with Basal-IQ Technology) which have been proven to reduce nocturnal hypoglycaemia by using predictive glucose alerts and a predictive low-glucose insulin suspension system [27,28].”
MethodNew and Emerging Technologies in Type 1 Diabetes
Sherwood, J. S., Russell, S. J., & Putman, M. S. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.07.006 · Cited by 49
Janež, A., Battelino, T., Klupa, T., Kocsis, G., Kuricova, M., Lalic, N. M., Stoian, A. P., Prázný, M., Rahelić, D., Šoupal, J., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01160-5 · Cited by 48
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 83
An overview of advancements in closed-loop artificial pancreas system
Dermawan, D., & Purbayanto, M. A. K. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11648 · Cited by 50
Passanisi, S., Lombardo, F., Mameli, C., Bombaci, B., Macedoni, M., Zuccotti, G., Dovč, K., Battelino, T., Salzano, G., & Delvecchio, M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01501-6 · Cited by 46
PAULEY, M. E., Tommerdahl, K. L., Snell‐Bergeon, J. K., & Forlenza, G. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01799-x · Cited by 46
Self-citationJacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A. X., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00358-x · Cited by 40
“Eight reported primary results 64 – 68, 70 – 72 and 3 were Limitations of data include the fact that several different algorithms for suspending insulin were tested, re fl ecting the rapid technological evolution of the fi eld.”
BackgroundAdvances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes
Dadlani, V., Pinsker, J. E., Dassau, E., & Kudva, Y. C. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1051-z · Cited by 32
Self-citationAlderisio, A., Bozzetto, L., Franco, L., Riccardi, G., Rivellese, A. A., & Annuzzi, G. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.06.008 · Cited by 36
The automated pancreas: A review of technologies and clinical practice
Biester, T., Tauschmann, M., Chobot, A. P., Kordonouri, O., Danne, T., Kapellen, T. M., & Dovč, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14576 · Cited by 34
“As the first step of AID, predictive suspension of insulin infusion using a pump-sensor combination has been available for people in all age groups for some time,(20) and a second scientifically tested system is also available from the age of 6 years with similar clinical success.(21)”
MethodElian, V., Popovici, V., Ozon, E.-A., Musuc, A. M., Fița, A. C., Rusu, E., Radulian, G., & Lupuliasa, D. (2023) · Life · doi:10.3390/life13081663 · Cited by 41
Insulin-delivery methods for children and adolescents with type 1 diabetes
Zuberi, Z., Sauli, E., Cun, L., Deng, J., Li, W., He, X.-L., & Li, W. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820906016 · Cited by 33
Hypoglycaemia in type 1 diabetes mellitus: risks and practical prevention strategies
Kaur, J., & Seaquist, E. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00762-8 · Cited by 38
Forlenza, G. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0077 · Cited by 32
Self-citationDave, D., Erraguntla, M., Lawley, M., DeSalvo, D. J., Haridas, B., McKay, S. V., & Koh, C. J. (2021) · JMIR Diabetes · doi:10.2196/26909 · Cited by 30
“Of note, data were obtained from a mix of patients using multiple daily injections, sensor-augmented pump therapy without automated basal rate modulation, and sensor-augmented pump therapy with a predictive low-glucose suspend feature (ie, t:slim X2 insulin pump with Basal-IQ technology; Tandem Diabetes Care, Inc [48]…”
MethodChen, E., King, F., Kohn, M. A., Spanakis, E. K., Breton, M. D., & Klonoff, D. C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0119 · Cited by 28
A Modular Safety System for an Insulin Dose Recommender: A Feasibility Study
Liu, C., Avari, P., Leal, Y., Wos, M., Sivasithamparam, K., Georgiou, P., Reddy, M., Fernández-Real, J., Martin, C. E., Fernández-Balsells, M., et al. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819851135 · Cited by 25
“to control glucose levels, such as sensor-augmented insulin pumps with low-glucose insulin suspend [3], the artificial pancreas [4], and decision support systems for insulin dosing [5].”
BackgroundMethod
Metadata
- Authors
- Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., Marcal, T., Andre, C., Carria, L., Swanson, V., Lum, J. W., Kollman, C., Woodall, W., & Beck, R. W.
- Affiliations
- University of Colorado Denver (US)
- Jaeb Center for Health Research (US)
- Stanford Medicine (US)
- Sansum Diabetes Research Institute (US)
- Yale University (US)
- Tandem Diabetes Care (United States) (US)
- Corresponding author
- Lum, John W.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-08
- Volume
- 41
- Issue
- 10
- Pages
- 2155-2161
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2886691517
- Cited by
- 246
- References
- 32
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 30 · 2023: 32 · 2022: 28 · 2021: 50 · 2020: 38 · 2019: 41 · 2018: 2
- FWCI
- 26.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, hypoglycemia, predictive low glucose suspend, continuous glucose monitoring, insulin pump therapy, sensor-augmented pump, glycemic control, adolescents, children
- MeSH terms
- Adolescent, Adult, Aged, Algorithms, Blood Glucose, Child, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Blood Glucose Self-Monitoring, Drug Delivery Systems, Cross-Over Studies, Monitoring, Ambulatory, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.